OCTAVE study update

Some of you will have been involved in the OCTAVE study, which has been investigating how effective vaccines against COVID-19 are for people with autoimmune conditions or on medication that affects their immune response. 

We have been delighted to be the patient partners on the study, representing children and young people with Juvenile Idiopathic Arthritis (JIA) and other conditions, and their families and working closely with the researchers and clinical teams. Two other patient representatives have focused on adults included in the study. 

Today we met in person for the first time, as part of the Scientific Summit. We discussed the work completed so far and the next steps and further analysis that is still needed to be completed. This study is a very large study, and encouragingly the findings have already been used to help shape policy to keep patients safe.

The first major full paper will be published soon, and we will share a link as soon as it is available. The paper includes a 'lay summary' and infographic, helping make some of the findings easier to access.

A huge thank you to everyone who has taken part and been involved in this vital research project. That includes children and young people, family members, adults, researchers, clinical teams and everyone else involved in making this study happen.

You can read our patient's perspective on taking part in OCTAVE here. 

Note the study is no longer recruiting new patients. Results will be shared very soon.